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Abstract Making sense of rapidly evolving evidence on
genetic associations is crucial to making genuine advances
in human genomics and the eventual integration of this
information in the practice of medicine and public health.
Assessment of the strengths and weaknesses of this
evidence, and hence the ability to synthesize it, has been
limited by inadequate reporting of results. The STrength-
ening the REporting of Genetic Association studies
(STREGA) initiative builds on the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement and provides additions to 12 of the 22
items on the STROBE checklist. The additions concern
population stratification, genotyping errors, modeling haplo-
type variation, Hardy–Weinberg equilibrium, replication,
selection of participants, rationale for choice of genes and
variants, treatment effects in studying quantitative traits,
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statistical methods, relatedness, reporting of descriptive
and outcome data, and the volume of data issues that are
important to consider in genetic association studies. The
STREGA recommendations do not prescribe or dictate how
a genetic association study should be designed but seek to
enhance the transparency of its reporting, regardless of
choices made during design, conduct, or analysis.
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Introduction
The rapidly evolving evidence on genetic associations is
crucial to integrating human genomics into the practice of
medicine and public health (Khoury et al. 2004; Genomics
Health and Society Working Group 2004). Genetic factors
are likely to affect the occurrence of numerous common
diseases, and therefore identifying and characterizing the
associated risk (or protection) will be important in
improving the understanding of etiology and potentially for
developing interventions based on genetic information. The
number of publications on the associations between genes
and diseases has increased tremendously; with more than
34,000 published articles, the annual number has more than
doubled between 2001 and 2008 (Lin et al. 2006; Yu et al.
2008). Articles on genetic associations have been published
in about 1,500 journals and in several languages.
Despite many similarities between genetic association
studies and ‘‘classical’’ observational epidemiologic studies
(that is, cross-sectional, case–control, and cohort) of life-
style and environmental factors, genetic association studies
present several specific challenges including an unprece-
dented volume of new data (Lawrence et al. 2005; Thomas
2006) and the likelihood of very small individual effects.
Genes may operate in complex pathways with gene-envi-
ronment and gene–gene interactions (Khoury et al. 2007).
Moreover, the current evidence base on gene-disease
associations is fraught with methodological problems
(Little et al. 2003; Ioannidis et al. 2005, 2006). Inadequate
reporting of results, even from well-conducted studies,
hampers assessment of a study’s strengths and weaknesses,
and hence the integration of evidence (von Elm and Egger
2004).
Although several commentaries on the conduct,
appraisal and/or reporting of genetic association studies
have so far been published (Nature Genetics 1999; Cardon
and Bell 2001; Weiss 2001; Weiss et al. 2001; Cooper et al.
2002; Hegele 2002; Little et al. 2002; Romero et al. 2002;
Colhoun et al. 2003; van Duijn and Porta 2003; Crossman
and Watkins 2004; Huizinga et al. 2004; Little 2004;
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Rebbeck et al. 2004; Tan et al. 2004; Anonymous 2005;
Ehm et al. 2005; Freimer and Sabatti 2005; Hattersley and
McCarthy 2005; Manly 2005; Shen et al. 2005; Vitali and
Randolph 2005; Wedzicha and Hall 2005; Hall and Blakey
2005; DeLisi and Faraone 2006; Saito et al. 2006; Uhlig
et al. 2007; NCI-NHGRI Working Group on Replication in
Association Studies et al. 2007), their recommendations
differ. For example, some papers suggest that replication of
findings should be part of the publication (Nature Genetics
1999; Cardon and Bell 2001; Cooper et al. 2002; Hegele
2002; Huizinga et al. 2004; Tan et al. 2004; Wedzicha and
Hall 2005; Hall and Blakey 2005; DeLisi and Faraone
2006), whereas others consider this suggestion unnecessary
or even unreasonable (van Duijn and Porta 2003; Begg
2005; Byrnes et al. 2005; Pharoah et al. 2005; Wacholder
2005; Whittemore 2005). In many publications, the guid-
ance has focused on genetic association studies of specific
diseases (Weiss 2001; Weiss et al. 2001; Hegele 2002;
Romero et al. 2002; Crossman and Watkins 2004; Huizinga
et al. 2004; Rebbeck et al. 2004; Tan et al. 2004; Manly
2005; Shen et al. 2005; Vitali and Randolph 2005; Wed-
zicha and Hall 2005; Hall and Blakey 2005; DeLisi and
Faraone 2006; Saito et al. 2006; Uhlig et al. 2007) or the
design and conduct of genetic association studies (Cardon
and Bell 2001; Weiss 2001; Weiss et al. 2001; Hegele
2002; Romero et al. 2002; Colhoun et al. 2003; Crossman
and Watkins 2004; Huizinga et al. 2004; Rebbeck et al.
2004; Hattersley and McCarthy 2005; Manly 2005; Shen
et al. 2005; Hall and Blakey 2005; DeLisi and Faraone
2006) rather than on the quality of the reporting.
Despite increasing recognition of these problems, the
quality of reporting genetic association studies needs to be
improved (Bogardus et al. 1999; Peters et al. 2003; Clark and
Baudouin 2006; Lee et al. 2007; Yesupriya et al. 2008). For
example, an assessment of a random sample of 315 genetic
association studies published from 2001 to 2003 found that
most studies provided some qualitative descriptions of the
study participants (for example, origin and enrollment cri-
teria), but reporting of quantitative descriptors such as age
and sex was variable (Yesupriya et al. 2008). In addition,
completeness of reporting of methods that allow readers to
assess potential biases (for example, number of exclusions or
number of samples that could not be genotyped) varied
(Yesupriya et al. 2008). Only some studies described meth-
ods to validate genotyping or mentioned whether research
staff was blinded to outcome. The same problems persisted
in a smaller sample of studies published in 2006 (Yesupriya
et al. 2008). Lack of transparency and incomplete reporting
have raised concerns in a range of health research fields (von
Elm and Egger 2004; Reid et al. 1995; Brazma et al. 2001;
Pocock et al. 2004; Altman and Moher 2005) and poor
reporting has been associated with biased estimates of effects
in clinical intervention studies (Gluud 2006).
The main goal of this article is to propose and justify a
set of guiding principles for reporting results of genetic
association studies. The epidemiology community has
recently developed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) State-
ment for cross-sectional, case–control, and cohort studies
(von Elm et al. 2007; Vandenbroucke et al. 2007). Given
the relevance of general epidemiologic principles for
genetic association studies, we propose recommendations
in an extension of the STROBE statement called the
STrengthening the REporting of Genetic Association
studies (STREGA) Statement. The recommendations of the
STROBE Statement have a strong foundation because they
are based on the empirical evidence on the reporting of
observational studies, and they involved extensive con-
sultations in the epidemiologic research community
(Vandenbroucke et al. 2007). We have sought to identify
gaps and areas of controversy in the evidence regarding
potential biases in genetic association studies. With the
recommendations, we have indicated available empirical or
theoretical work that has demonstrated or suggested that a
methodological feature of a study can influence the direc-
tion or magnitude of the association observed. We
acknowledge that for many items, no such evidence exists.
The intended audience for the reporting guideline is broad
and includes epidemiologists, geneticists, statisticians, cli-
nician scientists, and laboratory-based investigators who
undertake genetic association studies. In addition, it
includes ‘‘users’’ of such studies who wish to understand
the basic premise, design, and limitations of genetic asso-
ciation studies in order to interpret the results. The field of
genetic associations is evolving very rapidly with the
advent of genome-wide association investigations, high-
throughput platforms assessing genetic variability beyond
common single-nucleotide polymorphisms (SNPs) (for
example, copy number variants, rare variants), and even-
tually routine full sequencing of samples from large
populations. Our recommendations are not intended to
support or oppose the choice of any particular study design
or method. Instead, they are intended to maximize the
transparency, quality and completeness of reporting of
what was done and found in a particular study.
Methods
A multidisciplinary group developed the STREGA State-
ment using literature review, workshop presentations and
discussion, and iterative electronic correspondence after
the workshop. Thirty-three of 74 invitees participated in the
STREGA workshop in Ottawa, Ontario, Canada, in June,
2006. Participants included epidemiologists, geneticists,
statisticians, journal editors, and graduate students.
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Before the workshop, an electronic search was per-
formed to identify existing reporting guidance for genetic
association studies. Workshop participants were also asked
to identify any additional guidance. They prepared brief
presentations on existing reporting guidelines, empirical
evidence on reporting of genetic association studies, the
development of the STROBE Statement, and several key
areas for discussion that were identified on the basis of
consultations before the workshop. These areas included
the selection and participation of study participants, ratio-
nale for choice of genes and variants investigated,
genotyping errors, methods for inferring haplotypes, popu-
lation stratification, assessment of Hardy–Weinberg
equilibrium (HWE), multiple testing, reporting of quanti-
tative (continuous) outcomes, selectively reporting study
results, joint effects and inference of causation in single
studies. Additional resources to inform workshop partici-
pants were the HuGENet handbook (Little and Higgins
2006; Higgins et al. 2007), examples of data extraction
forms from systematic reviews or meta-analyses, articles
on guideline development (Altman et al. 2001; Moher et al.
2001) and the checklists developed for STROBE. To har-
monize our recommendations for genetic association
studies with those for observational epidemiologic studies,
we communicated with the STROBE group during the
development process and sought their comments on the
STREGA draft documents. We also provided comments on
the developing STROBE Statement and its associated
explanation and elaboration document (Vandenbroucke
et al. 2007).
Results
In Table 1, we present the STREGA recommendations, an
extension to the STROBE checklist (von Elm et al. 2007)
for genetic association studies. The resulting STREGA
checklist provides additions to 12 of the 22 items on the
STROBE checklist. During the workshop and subsequent
consultations, we identified five main areas of special
interest that are specific to, or especially relevant in,
genetic association studies: genotyping errors, population
stratification, modeling haplotype variation, HWE, and
replication. We elaborate on each of these areas, starting
each section with the corresponding STREGA recom-
mendation, followed by a brief outline of the issue and an
explanation for the recommendations. Complementary
information on these areas and the rationale for additional
STREGA recommendations relating to selection of par-
ticipants, choice of genes and variants selected, treatment
effects in studying quantitative traits, statistical methods,
relatedness, reporting of descriptive and outcome data, and
issues of data volume, are presented in Table 2.
Genotyping errors
Recommendation for reporting of methods (Table 1, item
8(b)): Describe laboratory methods, including source and
storage of DNA, genotyping methods and platforms
(including the allele calling algorithm used, and its ver-
sion), error rates, and call rates. State the laboratory/
center where genotyping was done. Describe comparability
of laboratory methods if there is more than one group.
Specify whether genotypes were assigned using all of the
data from the study simultaneously or in smaller batches.
Recommendation for reporting of results (Table 1, item
13(a)): Report numbers of individuals in whom genotyping
was attempted and numbers of individuals in whom geno-
typing was successful.
Genotyping errors can occur as a result of effects of the
DNA sequence flanking the marker of interest, poor quality
or quantity of the DNA extracted from biological samples,
biochemical artefacts, poor equipment precision or equip-
ment failure, or human error in sample handling, conduct
of the array or handling the data obtained from the array
(Pompanon et al. 2005). A commentary published in 2005
on the possible causes and consequences of genotyping
errors observed that an increasing number of researchers
were aware of the problem, but that the effects of such
errors had largely been neglected (Pompanon et al. 2005).
The magnitude of genotyping errors has been reported to
vary between 0.5 and 30% (Pompanon et al. 2005; Akey
et al. 2001; Dequeker et al. 2001; Mitchell et al. 2003). In
high-throughput centers, an error rate of 0.5% per genotype
has been observed for blind duplicates that were run on the
same gel (Mitchell et al. 2003). This lower error rate
reflects an explicit choice of markers for which genotyping
rates have been found to be highly repeatable and whose
individual polymerase chain reactions (PCR) have been
optimized. Non-differential genotyping errors, that is, those
that do not differ systematically according to outcome
status, will usually bias associations towards the null
(Rothman et al. 1993; Garcia-Closas et al. 2004), just as for
other non-differential errors. The most marked bias occurs
when genotyping sensitivity is poor and genotype preva-
lence is high ([85%) or, as the corollary, when genotyping
specificity is poor and genotype prevalence is low (\15%)
(Rothman et al. 1993). When measurement of the envi-
ronmental exposure has substantial error, genotyping errors
of the order of 3% can lead to substantial under-estimation
of the magnitude of an interaction effect (Wong et al.
2004). When there are systematic differences in genotyping
according to outcome status (differential error), bias in any
direction may occur. Unblinded assessment may lead to
differential misclassification. For genome-wide association
studies of SNPs, differential misclassification between
comparison groups (for example, cases and controls) can
134 Hum Genet (2009) 125:131–151
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Table 1 STREGA reporting recommendations, extended from STROBE Statement
Item Item number STROBE guideline Extension for Genetic
Association Studies
(STREGA)
Title and Abstract 1 (a) Indicate the study’s design with a
commonly used term in the title or the
abstract
(b) Provide in the abstract an informative and
balanced summary of what was done and
what was found
Introduction
Background rationale 2 Explain the scientific background and rationale
for the investigation being reported
Objectives 3 State specific objectives, including any pre-
specified hypotheses
State if the study is the first report of a
genetic association, a replication effort,
or both
Methods
Study design 4 Present key elements of study design early in
the paper
Setting 5 Describe the setting, locations and relevant
dates, including periods of recruitment,
exposure, follow-up, and data collection
Participants 6 (a) Cohort study: give the eligibility criteria,
and the sources and methods of selection of
participants. Describe methods of follow-up
Case–control study: give the eligibility criteria,
and the sources and methods of case
ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study: give the eligibility
criteria, and the sources and methods of
selection of participants
Give information on the criteria and methods
for selection of subsets of participants from
a larger study, when relevant
(b) Cohort study: for matched studies, give
matching criteria and number of exposed
and unexposed
Case–control study: for matched studies, give
matching criteria and the number of controls
per case
Variables 7 (a) Clearly define all outcomes, exposures,
predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if
applicable
(b) Clearly define genetic exposures (genetic
variants) using a widely-used
nomenclature system. Identify variables
likely to be associated with population
stratification (confounding by ethnic
origin)
Data sources measurement 8a (a) For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one
group
(b) Describe laboratory methods, including
source and storage of DNA, genotyping
methods and platforms (including the
allele calling algorithm used, and its
version), error rates and call rates. State the
laboratory/center where genotyping was
done. Describe comparability of laboratory
methods if there is more than one group.
Specify whether genotypes were assigned
using all of the data from the study
simultaneously or in smaller batches
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Table 1 continued
Item Item number STROBE guideline Extension for Genetic
Association Studies
(STREGA)
Bias 9 (a) Describe any efforts to address potential
sources of bias
(b) For quantitative outcome variables,
specify if any investigation of potential
bias resulting from pharmacotherapy was
undertaken. If relevant, describe the nature
and magnitude of the potential bias, and
explain what approach was used to deal
with this
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen, and
why
If applicable, describe how effects of
treatment were dealt with
Statistical methods 12 (a) Describe all statistical methods, including
those used to control for confounding
State software version used and options (or
settings) chosen
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were addressed
Cohort study: if applicable, explain how loss to
follow-up was addressed
Case–control study: if applicable, explain how
matching of cases and controls was
addressed
Cross-sectional study: if applicable, describe
analytical methods taking account of
sampling strategy
(e) Describe any sensitivity analyses
(f) State whether Hardy–Weinberg
equilibrium was considered and, if so, how
(g) Describe any methods used for inferring
genotypes or haplotypes
(h) Describe any methods used to assess or
address population stratification
(i) Describe any methods used to address
multiple comparisons or to control risk of
false-positive findings
(j) Describe any methods used to address and
correct for relatedness among subjects
Results
Participants 13a (a) Report the numbers of individuals at each
stage of the study—e.g., numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up, and analyzed
Report numbers of individuals in whom
genotyping was attempted and numbers of
individuals in whom genotyping was
successful
(b) Give reasons for non-participation at each
stage
(c) Consider use of a flow diagram
Descriptive data 14a (a) Give characteristics of study participants
(e.g., demographic, clinical, social) and
information on exposures and potential
confounders
Consider giving information by genotype
(b) Indicate the number of participants with
missing data for each variable of interest
(c) Cohort study: summarize follow-up time,
e.g., average and total amount
136 Hum Genet (2009) 125:131–151
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occur because of differences in DNA storage, collection or
processing protocols, even when the genotyping itself
meets the highest possible standards (Clayton et al. 2005).
In this situation, using samples blinded to comparison
group to determine the parameters for allele calling could
still lead to differential misclassification. To minimize such
Table 1 continued
Item Item number STROBE guideline Extension for Genetic
Association Studies
(STREGA)
Outcome data 15a Cohort study: report numbers of outcome
events or summary measures over time
Report outcomes (phenotypes) for each
genotype category over time
Case–control study: report numbers in each
exposure category, or summary measures of
exposure
Report numbers in each genotype category
Cross-sectional study: report numbers of
outcome events or summary measures
Report outcomes (phenotypes) for each
genotype category
Main results 16 (a) Give unadjusted estimates and, if
applicable, confounder-adjusted estimates
and their precision (e.g., 95% confidence
intervals). Make clear which confounders
were adjusted for and why they were
included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a
meaningful time period
(d) Report results of any adjustments for
multiple comparisons
Other analyses 17 (a) Report other analyses done—e.g., analyses
of subgroups and interactions, and
sensitivity analyses
(b) If numerous genetic exposures (genetic
variants) were examined, summarize
results from all analyses undertaken
(c) If detailed results are available elsewhere,
state how they can be accessed
Discussion
Key results 18 Summarize key results with reference to study
objectives
Limitations 19 Discuss limitations of the study, taking into
account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results
considering objectives, limitations,
multiplicity of analyses, results from similar
studies, and other relevant evidence
Generalizability 21 Discuss the generalizability (external validity)
of the study results
Other information
Funding 22 Give the source of funding and the role of the
funders for the present study and, if
applicable, for the original study on which
the present article is based
STREGA Strengthening the REporting of Genetic Association studies, STROBE Strengthening the Reporting of Observational Studies in
Epidemiology
a Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and
cross-sectional studies
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p
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p
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b
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p
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p
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b
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p
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at
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p
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m
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r
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m
in
o
r
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b
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in
te
rp
re
t
re
p
o
rt
ed
re
su
lt
s,
an
d
it
is
cr
it
ic
al
fo
r
re
p
ro
d
u
ci
n
g
th
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b
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at
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b
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at
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ca
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b
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b
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b
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is
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b
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d
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p
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b
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b
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p
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p
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p
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d
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p
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ra
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p
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at
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ra
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b
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b
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p
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at
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at
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b
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at
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at
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b
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at
is
ti
ca
l
te
st
s
o
r
m
ea
su
re
s
sh
o
u
ld
b
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d
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b
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at
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)
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p
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ra
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f
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ra
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e
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v
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b
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differential misclassification, it would be necessary to
calibrate the software separately for each group. This is one
of the reasons for our recommendation to specify whether
genotypes were assigned using all of the data from the
study simultaneously or in smaller batches.
Population stratification
Recommendation for reporting of methods (Table 1, item
12(h)): Describe any methods used to assess or address
population stratification.
Population stratification is the presence within a popu-
lation of subgroups among which allele (or genotype; or
haplotype) frequencies and disease risks differ. When the
groups compared in the study differ in their proportions of
the population subgroups, an association between the
genotype and the disease being investigated may reflect the
genotype being an indicator identifying a population sub-
group rather than a causal variant. In this situation,
population subgroup is a confounder because it is associ-
ated with both genotype frequency and disease risk. The
potential implications of population stratification for the
validity of genetic association studies have been debated
(Knowler et al. 1988; Gelernter et al. 1993; Kittles et al.
2002; Thomas and Witte 2002; Wacholder et al. 2002;
Cardon and Palmer 2003; Wacholder et al. 2000; Ardlie
et al. 2002; Edland et al. 2004; Millikan 2001; Wang et al.
2004; Ioannidis et al. 2004; Marchini et al. 2004; Freedman
et al. 2004; Khlat et al. 2004). Modeling the possible effect
of population stratification (when no effort has been made
to address it) suggests that the effect is likely to be small in
most situations (Wacholder et al. 2000; Ardlie et al. 2002;
Millikan 2001; Wang et al. 2004; Ioannidis et al. 2004).
Meta-analyses of 43 gene-disease associations comprising
697 individual studies showed consistent associations
across groups of different ethnic origin (Ioannidis et al.
2004), and thus provide evidence against a large effect of
population stratification, hidden or otherwise. However, as
studies of association and interaction typically address
moderate or small effects and hence require large sample
sizes, a small bias arising from population stratification
may be important (Marchini et al. 2004). Study design
(case-family control studies) and statistical methods
(Balding 2006) have been proposed to address population
stratification, but so far few studies have used these sug-
gestions (Yesupriya et al. 2008). Most of the early genome-
wide association studies used family-based designs or such
methods as genomic control and principal components
analysis (Wellcome Trust Case Control Consortium 2007;
Ioannidis 2007) to control for stratification. These
approaches are particularly appropriate for addressing bias
when the identified genetic effects are very small (odds
ratio \ 1.20), as has been the situation in many recent
genome-wide association studies (Wellcome Trust Case
Control Consortium 2007; Parkes et al. 2007; Todd et al.
2007; Zeggini et al. 2007; Diabetes Genetics Initiative of
Broad Institute of Harvard and MIT, Lund University, and
Novartis Institutes of BioMedical Research et al. 2007;
Scott et al. 2007; Helgadottir et al. 2007; McPherson et al.
2007; Easton et al. 2007; Hunter et al. 2007; Stacey et al.
2007; Gudmundsson et al. 2007; Haiman et al. 2007b;
Yeager et al. 2007; Zanke et al. 2007; Tomlinson et al.
2007; Haiman et al. 2007a; Rioux et al. 2007; Libioulle
et al. 2007; Duerr et al. 2006). In view of the debate about
the potential implications of population stratification for
the validity of genetic association studies, we recommend
transparent reporting of the methods used, or stating that
none was used, to address this potential problem. This
reporting will enable empirical evidence to accrue about
the effects of population stratification and methods to
address it.
Modeling haplotype variation
Recommendation for reporting of methods (Table 1, item
12(g)): Describe any methods used for inferring genotypes
or haplotypes.
A haplotype is a combination of specific alleles at
neighboring genes that tends to be inherited together. There
has been a considerable interest in modeling haplotype
variation within candidate genes. Typically, the number of
haplotypes observed within a gene is much smaller than the
theoretical number of all possible haplotypes (Zhao et al.
2003; International HapMap Consortium et al. 2007).
Motivation for utilizing haplotypes comes, in large part,
from the fact that multiple SNPs may ‘‘tag’’ an untyped
variant more effectively than a single typed variant. The
subset of SNPs used in such an approach is called ‘‘haplo-
type tagging’’ SNPs. Implicitly, an aim of haplotype
tagging is to reduce the number of SNPs that have to be
genotyped, while maintaining statistical power to detect an
association with the phenotype. Maps of human genetic
variation are becoming more complete, and large-scale
genotypic analysis is becoming increasingly feasible. In
consequence, it is possible that modeling haplotype varia-
tion will become more focussed on rare causal variants,
because these may not be included in the genotyping
platforms.
In most current large-scale genetic association studies,
data are collected as unphased multilocus genotypes (that
is, which alleles are aligned together on particular seg-
ments of chromosome is unknown). It is common in such
studies to use statistical methods to estimate haplotypes
(Stephens et al. 2001; Qin et al. 2002; Scheet and Stephens
2006; Browning 2008), and their accuracy and efficiency
have been discussed (Huang et al. 2003; Kamatani et al.
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2004; Zhang et al. 2004; Carlson et al. 2004; van Hylckama
Vlieg et al. 2004). Some methods attempt to make use of a
concept called haplotype ‘‘blocks’’ (Greenspan and Geiger
2004; Kimmel and Shamir 2005), but the results of these
methods are sensitive to the specific definitions of the
‘‘blocks’’ (Cardon and Abecasis 2003; Ke et al. 2004).
Reporting of the methods used to infer individual haplo-
types and population haplotype frequencies, along with
their associated uncertainties should enhance our under-
standing of the possible effects of different methods of
modeling haplotype variation on study results as well as
enabling comparison and syntheses of results from differ-
ent studies.
Information on common patterns of genetic variation
revealed by the International Haplotype Map (HapMap)
Project (International HapMap Consortium et al. 2007) can
be applied in the analysis of genome-wide association
studies to infer genotypic variation at markers not typed
directly in these studies (Servin and Stephens 2007; Mar-
chini et al. 2007). Essentially, these methods perform
haplotype-based tests but make use of information on
variation in a set of reference samples (for example,
HapMap) to guide the specific tests of association, col-
lapsing a potentially large number of haplotypes into two
classes (the allelic variation) at each marker. It is expected
that these techniques will increase power in individual
studies, and will aid in combining data across studies, and
even across differing genotyping platforms. If imputation
procedures have been used, it is useful to know the method,
accuracy thresholds for acceptable imputation, how impu-
ted genotypes were handled or weighted in the analysis,
and whether any associations based on imputed genotypes
were also verified on the basis of direct genotyping at a
subsequent stage.
Hardy–Weinberg equilibrium
Recommendation for reporting of methods (Table 1, item
12(f)): State whether HWE was considered and, if so, how.
Hardy–Weinberg equilibrium has become widely
accepted as an underlying model in population genetics
after (Hardy 1908) and (Weinberg 1908) proposed the
concept that genotype frequencies at a genetic locus are
stable within one generation of random mating; the
assumption of HWE is equivalent to the independence of
two alleles at a locus. Views differ on whether testing
for departure from HWE is a useful method to detect
errors or peculiarities in the data set, and also the
method of testing (Minelli et al. 2008). In particular, it
has been suggested that deviation from HWE may be a
sign of genotyping errors (Xu et al. 2002; Hosking et al.
2004; Salanti et al. 2005). Testing for departure from
HWE has a role in detecting gross errors of genotyping
in large-scale genotyping projects such as identifying
SNPs for which the clustering algorithms used to call
genotypes have broken down (Wellcome Trust Case
Control Consortium 2007; Pearson and Manolio 2008).
However, the statistical power to detect less important
errors of genotyping by testing for departure from HWE
is low (McCarthy et al. 2008) and, in hypothetical data,
the presence of HWE was generally not altered by the
introduction of genotyping errors (Zou and Donner
2006). Furthermore, the assumptions underlying HWE,
including random mating, lack of selection according to
genotype, and absence of mutation or gene flow, are
rarely met in human populations (Shoemaker et al. 1998;
Ayres and Balding 1998). In five of 42 gene-disease
associations assessed in meta-analyses of almost 600
studies, the results of studies that violated HWE signif-
icantly differed from the results of studies that
conformed to the model (Trikalinos et al. 2006). More-
over, the study suggested that the exclusion of HWE-
violating studies may result in loss of the statistical
significance of some postulated gene-disease associations
and that adjustment for the magnitude of deviation from
the model may also have the same consequence for some
other gene-disease associations. Given the differing
views about the value of testing for departure from HWE
and about the test methods, transparent reporting of
whether such testing was done and, if so, the method
used, is important for allowing the empirical evidence to
accrue.
For massive-testing platforms, such as genome-wide
association studies, it might be expected that many false-
positive violations of HWE would occur if a lenient P
value threshold were set. There is no consensus on the
appropriate P value threshold for HWE-related quality
control in this setting. Hence, we recommend that inves-
tigators state which threshold they have used, if any, to
exclude specific polymorphisms from further consider-
ation. For SNPs with low minor allele frequencies,
substantially more significant results than expected by
chance have been observed, and the distribution of alleles
at these loci has often been found to show departure from
HWE.
For genome-wide association studies, another approach
that has been used to detect errors or peculiarities in the
data set (due to population stratification, genotyping error,
HWE deviations or other reasons) has been to construct
quantile–quantile (Q/Q) plots whereby observed associa-
tion statistics or calculated P values for each SNP are
ranked in order from smallest to largest and plotted
against the expected null distribution (Pearson and
Manolio 2008; McCarthy et al. 2008). The shape of the
curve can lend insight into whether or not systematic
biases are present.
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Replication
Recommendation: state if the study is the first report of a
genetic association, a replication effort, or both (Table 1,
item 3).
Articles that present and synthesize data from several
studies in a single report are becoming more common. In
particular, many genome-wide association analyses
describe several different study populations, sometimes
with different study designs and genotyping platforms, and
in various stages of discovery and replication (Pearson and
Manolio 2008; McCarthy et al. 2008). When data from
several studies are presented in a single original report,
each of the constituent studies and the composite results
should be fully described. For example, a discussion of
sample size and the reason for arriving at that size would
include clear differentiation between the initial group
(those that were typed with the full set of SNPs) and those
that were included in the replication phase only (typed with
a reduced set of SNPs) (Pearson and Manolio 2008;
McCarthy et al. 2008). Describing the methods and results
in sufficient detail would require substantial space in print,
but options for publishing additional information on the
study online make this possible.
Discussion
The choices made for study design, conduct and data
analysis potentially influence the magnitude and direction
of results of genetic association studies. However, the
empirical evidence on these effects is insufficient. Trans-
parency of reporting is, thus, essential for developing a
better evidence base (Table 2). Transparent reporting helps
address gaps in empirical evidence (Bogardus et al. 1999),
such as the effects of incomplete participation and geno-
typing errors. It will also help assess the impact of
currently controversial issues such as population stratifi-
cation, methods of inferring haplotypes, departure from
HWE and multiple testing on effect estimates under dif-
ferent study conditions.
The STREGA Statement proposes a minimum checklist
of items for reporting genetic association studies. The
statement has several strengths. First, it is based on existing
guidance on reporting observational studies (STROBE).
Second, it was developed from discussions of an interdis-
ciplinary group that included epidemiologists, geneticists,
statisticians, journal editors, and graduate students, thus
reflecting a broad collaborative approach in terminology
accessible to scientists from diverse disciplines. Finally, it
explicitly describes the rationale for the decisions (Table 2)
and has a clear plan for dissemination and evaluation.
The STREGA recommendations are available at
www.strega-statement.org. We welcome comments, which
will be used to refine future versions of the recommenda-
tions. We note that little is known about the most effective
ways to apply reporting guidelines in practice, and that
therefore it has been suggested that editors and authors
collect, analyze, and report their experiences in using such
guidelines (Davidoff et al. 2008). We consider that the
STREGA recommendations can be used by authors, peer
reviewers and editors to improve the reporting of genetic
association studies. We invite journals to endorse STRE-
GA, for example by including STREGA and its Web
address in their Instructions for Authors and by advising
authors and peer reviewers to use the checklist as a guide.
It has been suggested that reporting guidelines are most
helpful if authors keep the general content of the guideline
items in mind as they write their initial drafts, then refer to
the details of individual items as they critically appraise
what they have written during the revision process (Da-
vidoff et al. 2008). We emphasize that the STREGA
reporting guidelines should not be used for screening
submitted manuscripts to determine the quality or validity
of the study being reported. Adherence to the recommen-
dations may make some manuscripts longer, and this may
be seen as a drawback in an era of limited space in a print
journal. However, the ability to post information on the
Web should alleviate this concern. The place in which
supplementary information is presented can be decided by
authors and editors of the individual journal.
We hope that the recommendations stimulate transpar-
ent and improved reporting of genetic association studies.
In turn, better reporting of original studies would facilitate
the synthesis of available research results and the further
development of study methods in genetic epidemiology
with the ultimate goal of improving the understanding of
the role of genetic factors in the cause of diseases.
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